What Backs the Equity

What Backs the Equity

Figures converted from CHF at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Sonova spent ~$1.57bn near the cycle top — $1.22bn of buybacks at ~$344 and $352m on Sennheiser now exiting at a $133m loss — on top of an equity base that is ~100% intangible (tangible book $18.5m, goodwill ~87% of the $3,296m equity), so a questionable capital-allocation record sits over no asset floor. The buyback timing and the Sennheiser round-trip are documented in Owners and Stewards; this chapter measures what is left underneath that equity, and what protects it.

For a bankruptcy-averse, asset-minded reader the stake is concrete. The blended ~$344 buyback price sits about 34% above the $257 the shares fetch today, and the $133m Sennheiser discontinued-operations loss is roughly 19% of the $682.8m of continuing profit. With tangible book at $18.5m there is no asset floor to fall back on, so the downside protection an asset-minded investor looks for comes from the liability side and the cash flows — net debt near 1.2x normalised EBITA and profit-to-cash conversion close to 95% — not from book value. The counter-fact sits in the same frame: the buybacks shrank the share count about 7.4%, net debt has been cut from $1,632m to $1,243m, return on capital employed is 19.0%, and the goodwill clears its impairment tests with no impairment recognised on a pre-tax discount rate raised to 10.9% in Hearing Instruments, the disclosed +1pp/-1pp sensitivity still clearing.

The equity is made of goodwill

At 31 March 2026 the balance sheet carries $3,277.8m of intangible assets and goodwill against total equity of $3,296.1m [1]. Subtract one from the other and tangible book value is $18.5m — and to shareholders of the parent (equity of $3,268.5m) it is slightly negative. Goodwill alone is $2,856.6m, roughly 87% of book equity and 41% of total assets [2].

Source: Consolidated balance sheet [3] and Note 3.5 intangible assets [4], Annual Report 2025/26. Tangible net assets = total equity less intangible assets and goodwill.

Source: Consolidated balance sheet [5], Annual Report 2025/26.

For an investor who screens for asset backing, the reading is direct: there is no net asset floor under this equity. That places Sonova firmly on the franchise side of the ledger rather than the depressed-asset side — the value here is the durability of the cash flows the goodwill represents, not what the balance sheet would fetch in a break-up.

Tangible book went $900m negative, then recovered

Tangible book value was actually positive at 31 March 2021 ($372m), then fell to roughly $902m negative by March 2023 before climbing back to zero. Two forces drove the swing, and both are already documented elsewhere in this report. The Sennheiser Consumer Hearing acquisition in 2022 added goodwill and an indefinite-life brand intangible, pushing intangibles to a $3,336m peak. At the same time the buy-high buyback programme and dividend returned more cash than the business retained, shrinking book equity — treasury shares rose from $325m to $780m across FY2022 alone [6].

Source: Consolidated balance sheets [7] [8] [9], Annual Reports 2021/22 through 2025/26. Values are year-end (31 March), each converted at its period-end rate.

The recovery toward zero in FY2026 came as intangibles ran off faster than equity — the Sennheiser brand intangible ($123m) moved to assets held for sale ahead of the divestment, and amortisation continued [10]. The mechanics matter for interpretation: negative tangible book here was manufactured by capital returns and one round-trip acquisition, not by operating losses eroding a real asset base. It reverses as those two effects unwind, which is what the last three years show. This is the balance-sheet footprint of the capital-allocation record set out in Owners and Stewards.

How solid the goodwill is

A book that is 87% goodwill is only as sound as the impairment tests behind it. Those tests have held with room. No goodwill impairment was recognised in FY2025/26 or FY2024/25 for continuing operations, and management raised the discount rate materially rather than flattering the assumptions: the Hearing Instruments pre-tax WACC went to 10.9% from 9.6%, and Cochlear Implants to 9.8% from 9.0%, both on an unchanged long-term growth rate near 2.1% [11]. The disclosed sensitivity — a further +1 point on the discount rate or −1 point on growth — still produces no impairment in either unit.

Source: Note 3.5 goodwill impairment testing [12], Annual Report 2025/26.

The one impairment actually taken this year was $43.4m against software that "will no longer deliver the economic benefits originally anticipated" — a write-down inside the normalisation add-backs flagged in Financials and Estimates, not a goodwill event [13]. The thinner cushion sits in Cochlear Implants: $322m of goodwill rests on a unit whose reported segment economics are deteriorating — the margin path and China volume-based procurement are set out in Segment Economics. The tests pass today, but this is the goodwill most exposed if that decline steepens.

The live tail: Advanced Bionics

The provisions note carries one genuine legacy liability — product-liability claims tied to the Advanced Bionics cochlear-implant recall of 2006 and a 2020 field corrective action, a recurring key audit matter for years [14]. The provision had run down steadily, from $102.1m in 2022 to $32.2m in 2025. In FY2025/26 it turned back up, as reassessment of the expected number and cost of claims added $32.4m, lifting the balance to $45.6m [15].

Sources: Key Audit Matters [16] [17] and Note 3.7 product liabilities [18], Annual Reports 2021/22–2025/26. Each year converted at its period-end rate.

The scale is contained: $45.6m is about 1.4% of equity and roughly 0.3% of market capitalisation, with the main cash outflow expected within three years [19]. Two things keep it on the watch list rather than filed away. It moved the wrong way this year after a multi-year run-off, and for the 2006 recall the note states that, allowing for limitation periods, claims have until 2026 to be filed in most jurisdictions — the window is closing during the current year, and settlement can run beyond it. It is a tail to track, not a threat to the balance sheet.

Where the margin of safety actually sits

Pulling the strands together: because there is no tangible asset backing, the downside protection an asset-minded investor looks for has to come from somewhere else. Here it comes from the liability side and the cash flows, not the assets. Net debt of roughly $1.24bn sits near 1.2x normalised EBITA, and the business converts profit to cash at close to 95% with capital expenditure below 3% of sales — the detail is in Financials and Estimates. That combination, not book value, is what makes the bankruptcy risk remote.

The measured read: the near-zero tangible book is a feature of a capital-light, acquisitive franchise that has returned a lot of cash, not a warning sign — and the goodwill behind it is well supported, clearing its tests on a raised discount rate with a stated cushion. The strongest fact against complacency is that goodwill and acquisition intangibles still equal the entire equity base, so any genuine deterioration in Hearing Instruments cash flows would fall on a book with no tangible buffer beneath it, and the Cochlear Implants goodwill is already the thin spot. What would change the read is a goodwill impairment — most plausibly in Cochlear Implants — or a further step-up in the Advanced Bionics provision as the claims window closes.